Efficacy and Safety of VB119 in Subjects With Minimal Change Disease and Focal Segmental Glomerulosclerosis
Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on
the maintenance of remission and duration of response in adults with primary MCD or primary
FSGS who previously responded to steroid therapy.